BridgeBio Pharma, Inc. · NASDAQ:BBIO

BridgeBio Pharma — Technical Presentation (September 2023)

11 slides from BridgeBio Pharma's technical presentation, Sep 12, 2023

  1. Slide 1: Oral infigratinib well tolerated and increases height velocity in children with achondroplasia

    Oral infigratinib treatment is well tolerated and significantly increases height velocity in children with achondroplasia: Month 6 results from the PROPEL 2 dose-finding study Ravi Savarirayan1, Josep Maria De Bergua2, Paul Arundel3, Jean Pierre Salles4, Vrinda Saraff5, Borja Delgado6, Antonio Leiva

  2. Slide 2: Disclaimers

    Disclaimers • Infigratinib has not been approved by the FDA or any other regulatory authority for the treatment of achondroplasia, as its efficacy and safety have not yet been established • Dr Melita Irving has the following potential conflicts of interest to disclose: − Advisory board member: Ascen

  3. Slide 3: Achondroplasia: the most common short-limbed skeletal dysplasia

    Achondroplasia: the most common short-limbed skeletal dysplasia • Achondroplasia (ACH) affects between 1 in 15,000 and 1 in 30,000 live births, with an estimated global prevalence of 250,0001,2 • Characteristic clinical features include disproportionate short stature, smaller than average chest, mac

  4. Slide 4: Infigratinib is an oral, selective FGFR1–3 inhibitor in development for achondroplasia

    Infigratinib is an oral, selective FGFR1–3 inhibitor in development as a treatment option for achondroplasia Mechanism of action Infigratinib FGFR3 NPR2 • Orally-available, selective, G380R ATP-competitive FGFR- mutation selective tyrosine kinase inhibitor • Selective for FGFR 1, 2 & 3 TK RAS RAF •

  5. Slide 5: Month 6 results from the dose escalation portion of the Phase 2 PROPEL 2 study

    Month 6 results from the dose escalation portion of the Phase 2 PROPEL 2 study • N=72; 42 females • Mean ± SD (range) age at consent = Mean ± SD (range) age at consent, 7.5 ± 2.2 (3.1–11.5) • 5 dose levels explored: • Cohort 1: 0.016 mg/kg/day • Cohort 2: 0.032 mg/kg/day • Cohort 3: 0.064 mg/kg/day

  6. Slide 6: Summary of adverse events

    Summary of adverse events • Treatment with infigratinib was well tolerated • No serious adverse events (SAEs) and no AEs that required treatment discontinuation • 71/72 (98.6%) children presented with at least 1 treatment-emergent AE (TEAE): – Most TEAEs were grade 1 (58.3%) and 2 (34.7%) in severit

  7. Slide 7: Infigratinib demonstrated significant, dose-responsive increases in annualized height velocity

    Infigratinib demonstrated significant, dose-responsive increases in annualized height velocity compared with baseline levels Mean (SE) change from baseline in annualized height velocity at month 6 cm/year Cohort 5 n=12 4 Female:Male ratio 7:5 3.5 3 +3.38 Mean age (year) 7.24 P=0.001 <5 8% 2.5 5 to <

  8. Slide 8: Month 6 changes in height z-score and body proportions compared with baseline

    Month 6 changes in height z-score and body proportions compared with baseline levels Baseline Height z-score change (ACH growth curve) Month 6 Mean (SE) Mean upper to lower body segment ratio 2.15 2.12 0.35 2.1 2.06 2.05 0.3 2.05 +0.29 2 0.25 2 1.98 P=0.0003 0.2 1.95 1.9 0.15 1.84 1.85 0.1 +0.11 1.8

  9. Slide 9: Summary

    Summary • Treatment with oral infigratinib has been well tolerated, with no SAEs, or TEAEs that led to treatment discontinuation • At Cohort 5 dose level, (0.25 mg/kg/day) – No hyperphosphatemia – No ocular AEs (i.e., no retinal or corneal disorders) – No accelerated progression of bone age – No wor

  10. Slide 10: Conclusions

    Conclusions The safety and efficacy of an oral, once-daily dose of infigratinib at 0.25 mg/kg/day will be explored further in a phase 3, randomized, controlled trial The 6-month observational lead-in to the phase 3 trial is open for enrollment If these phase 2 data are confirmed, infigratinib could

  11. Slide 11: Thank You

    THANK YOU

BridgeBio Pharma — Technical Presentation (September 2023) on 6ix